Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,477,000
-24,000 (-1.60%)
At close: Sep 3, 2026

Samsung Biologics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
1,984,3121,784,3521,083,316857,691798,056393,589
Depreciation & Amortization
498,676633,637599,101489,782308,264161,789
Loss (Gain) From Sale of Assets
5,7975,4542,1993,8662,5887,466
Asset Writedown & Restructuring Costs
5,24410,69762,655--725.89
Loss (Gain) From Sale of Investments
--759.34-597.28-5,152-72,653-269.12
Loss (Gain) on Equity Investments
-1,197-43,071-2,660499.42-27,260-13,853
Provision & Write-off of Bad Debts
-169.27-811.8-6,38021,51122,4074,857
Other Operating Activities
46,456-10,197-33,004-711.89185,130135,132
Change in Accounts Receivable
-7,750292,751-450,99230,127-305,336-120,660
Change in Inventory
-256,469-388,182-236,200-273,896-179,912-370,571
Change in Accounts Payable
-28,447-226,269409,295267,037134,59421,060
Change in Unearned Revenue
-45,20037,15710.5827,19944,017-
Change in Other Net Operating Assets
232,684153,049232,511248,27643,151235,330
Operating Cash Flow
2,433,9352,247,8071,659,2551,666,229953,048454,596
Operating Cash Flow Growth
4.18%35.47%-0.42%74.83%109.65%124.95%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-805,580-1,391,741-1,303,573-995,071-956,840-406,254
Sale of Property, Plant & Equipment
460.511,6371,3892,81164.0137.64
Cash Acquisitions
-533,668--601,956-1,071,525-1,081,821-
Sale (Purchase) of Intangibles
-50,179-83,333-73,952-110,254-52,386-14,898
Investment in Securities
-996,324-388,989734,318607,760-1,015,673-512,375
Other Investing Activities
-0-0-0-0178.52-0
Investing Cash Flow
-2,385,291-1,862,426-1,243,776-1,566,305-3,106,477-933,489

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-40,000237,000758,500593,75050,000
Long-Term Debt Issued
-45,000892,65945,000211,903648,356
Total Debt Issued
84,45385,0001,129,659803,500805,653698,356
Short-Term Debt Repaid
--130,000-684,500-686,783-496,988-30,000
Long-Term Debt Repaid
--267,075-878,947-751,967-496,906-171,734
Total Debt Repaid
-286,665-397,075-1,563,447-1,438,750-993,894-201,734
Net Debt Issued (Repaid)
-202,212-312,075-433,788-635,250-188,241496,622
Issuance of Common Stock
----3,200,751-
Repurchase of Common Stock
-92,013-92,013----
Other Financing Activities
-216,417-216,417-200-12,430-0
Financing Cash Flow
-510,641-620,504-433,788-635,0503,000,080496,622

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
41,093-7,24741,59312,245-3,242831.1
Net Cash Flow
-420,903-242,37023,284-522,882843,40918,560

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,628,355856,067355,682671,158-3,79248,343
Free Cash Flow Growth
256.70%140.68%-47.01%---22.56%
Free Cash Flow Margin
31.80%18.79%10.17%18.17%-0.13%3.08%
Free Cash Flow Per Share
37384.2419642.227683.6214498.68-83.521123.38
Levered Free Cash Flow
1,295,225515,49366,655-446,65321,97862,860
Unlevered Free Cash Flow
1,315,564533,72587,982-395,65562,01972,052

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
34,62137,08162,08663,48633,94018,594
Cash Income Tax Paid
595,819602,362307,026319,321188,47342,369
Change in Working Capital
-105,183-131,493-45,375298,743-263,485-234,840